Loading
A phase 3 trial of Carfilzomib, Pomalidomide, Elotuzumab in multiple myeloma, run by AbbVie, active and no longer recruiting.
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06158841 by AbbVie, with 421 participants enrolled, started 2024-05-19 and due to reach its primary completion in 2027-12. Interventions recorded: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Elotuzumab, Carfilzomib, Pomalidomide, Bortezomib.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
Shares Selinexor, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Relapsed or refractory multiple myeloma.